{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T01:23:28Z","timestamp":1779153808329,"version":"3.51.4"},"reference-count":9,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Levocetirizine is classified as a second\u2010generation antihistamine. Levocetirizine is available for the treatment of allergic disorders such as allergic rhinitis and chronic idiopathic urticaria. This was a single\u2010center, single\u2010dose, open\u2010label, randomized, 2\u2010way crossover study in healthy Japanese male subjects consisting of 2 parts. Part 1 compared the bioavailability of levocetirizine oral disintegrating tablet (ODT) and levocetirizine immediate\u2010release tablet (IRT) taken with water in the fasted state in 24 subjects; all subjects completed this part of the trial. In part 2, the bioavailability of levocetirizine ODT without water was compared with that of levocetirizine IRT with water in the fasted state in 48 subjects; 47 subjects completed this part of the trial. Bioequivalence was demonstrated between levocetirizine IRT 5 mg and ODT 5 mg. The safety profiles were generally similar between levocetirizine ODT and levocetirizine IRT, with no serious adverse events, deaths, or adverse events leading to withdrawal reported during the study.<\/jats:p>","DOI":"10.1002\/cpdd.791","type":"journal-article","created":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T18:17:04Z","timestamp":1584728224000},"page":"805-812","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Levocetirizine Oral Disintegrating Tablet: A Randomized Open\u2010Label Crossover Bioequivalence Study in Healthy Japanese Volunteers"],"prefix":"10.1002","volume":"9","author":[{"given":"Hiroko","family":"Ino","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Office Japan Development Division GlaxoSmithKline KK  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanari","family":"Shiramoto","sequence":"additional","affiliation":[{"name":"Souseikai Hakata Clinic  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Eto","sequence":"additional","affiliation":[{"name":"Souseikai Hakata Clinic  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miwa","family":"Haranaka","sequence":"additional","affiliation":[{"name":"Souseikai Hakata Clinic  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Irie","sequence":"additional","affiliation":[{"name":"Souseikai Hakata Clinic  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Terao","sequence":"additional","affiliation":[{"name":"Biomedical Data Sciences Department Japan Development Division GlaxoSmithKline KK  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Ogura","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Office Japan Development Division GlaxoSmithKline KK  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Wakamatsu","sequence":"additional","affiliation":[{"name":"Pre\u2010Clinical Development Department Japan Development Division GlaxoSmithKline KK  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Hoyano","sequence":"additional","affiliation":[{"name":"Biomedical Data Sciences Department Japan Development Division GlaxoSmithKline KK  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Nakano","sequence":"additional","affiliation":[{"name":"Immuno\u2010Inflammation Therapeutic Office Medicines Development Japan Development GlaxoSmithKline KK  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,3,20]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666070-00017"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.61.2.391"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2745.2002.01444.x"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280100364"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.3999\/jscpt.41.309"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847040-00001"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.4103\/0976-9668.71663"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2010.10.019"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/21556660.2014.928302"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpdd.791","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.791","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.791","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T15:28:59Z","timestamp":1693754939000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,20]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1002\/cpdd.791"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.791","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,20]]},"assertion":[{"value":"2019-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}